Cellebrite DI Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLBT research report →
Range $12.5 – $15
Price Chart
About the company
Cellebrite DI Ltd. delivers specialized digital intelligence solutions crafted for legally authorized investigations. Their comprehensive DI platform enables users to efficiently gather, scrutinize, interpret, and oversee digital information throughout the investigative process.
- CEO
- Shiv Ramji
- IPO
- 2020
- Employees
- 1,285
- HQ
- Petah Tikva, HM, IL
Get TickerSpark's AI analysis on CLBT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.71B
- P/E
- 40.70
- Fwd P/E
- 36.65
- PEG
- -2.52
- P/S
- 5.04
- P/B
- 4.96
- EV/EBITDA
- 20.41
- Div Yield
- 0.00%
- Gross Margin
- 82.26%
- Op Margin
- 11.99%
- Net Margin
- 12.14%
- ROE
- 12.35%
- ROIC
- 7.47%
Latest fiscal year · YoY change
- Revenue
- $475.68M+18.6%
- Gross Profit
- $400.50M+18.3%
- Op Income
- $66.48M
- Net Income
- $78.33M+127.7%
- EPS
- $0.31+123.0%
- OCF Growth
- +27.8%
- FCF Growth
- +28.1%
- 52W High
- $19.39
- 52W Low
- $9.58
- 50D MA
- $11.57
- 200D MA
- $13.13
- Beta
- 1.05
- RSI (14)
- 40
- Avg Volume
- 2.37M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cellebrite delivered a better-than-expected Q3 with ARR, revenue and adjusted EBITDA above guidance, while the company leaned further into Genesis, AI and a U.S. redomiciliation plan.· November 12, 2026
- Q3 ARR rose 20% to $528.5 million, with revenue of $149 million, gross profit of $127.7 million and adjusted EBITDA of $53.6 million all above guidance.
- Genesis was the standout new product, reaching $2 million of ARR in its first full quarter and driving early customer interest in AI-powered investigations.
- International growth remained strong, with EMEA up 22% and Asia-Pacific up 31%; U.S. Federal also reaccelerated to 18% growth.
- Management said Inseyets conversions improved to 75% of the install base, though the final tranche is expected to be a lighter uplift.
- Corellium remained a drag, with delayed renewals, higher churn and limited new sales tied to foreign-filer concerns.
- The company raised full-year adjusted EBITDA guidance, reaffirmed ARR, and narrowed revenue outlook toward more ratable cloud/AI revenue and less hardware.
Q3 ARR grew 20% to $528.5 million, above the high end of guidance. Revenue was $149 million, up 18% year over year. Gross profit increased 20% to $127.7 million, with gross margin of 85.7%. Adjusted EBITDA rose 42% to $53.6 million; operating income was $51.5 million and net income was $45.6 million, or $0.17 per diluted share. Free cash flow was $52 million in Q3 and $166 million over the trailing 12 months, a 31% margin; cash, cash equivalents and investments totaled $593 million at quarter-end. For Q4, revenue is guided to $145 million to $150 million and adjusted EBITDA to $47 million to $50 million. For the full year, revenue is guided to $553 million to $558 million, implying 16% to 17% growth, adjusted EBITDA to $163 million to $166 million, and free cash flow margin of approximately 30%. Full-year ARR is reaffirmed at $550 million to $560 million, with management saying it has higher confidence in the lower end of that range.
Shiven Ramji said Q3 showed better execution across ARR, revenue and profitability, driven by international momentum, improving U.S. Federal growth and disciplined spending. He emphasized Genesis as the centerpiece of the company’s future, saying it is already gaining traction and that customers are reprioritizing budgets to fund it. His tone was confident but measured: he highlighted a stronger product roadmap, more AI across the stack, and a 2027 Genesis platform vision, while also noting disappointment with Corellium and saying Q3 was progress, not the finish line.
David Barter focused on the financial beat and the mix shift toward ratable revenue. He cited Q3 ARR of $528.5 million, revenue of $149 million, gross profit of $127.7 million at 85.7% margin, adjusted EBITDA of $53.6 million, and free cash flow of $52 million in the quarter, with $593 million in cash and investments at September end. He said hardware and non-recurring revenue has been moving around, with more cloud and AI content ratabilizing revenue, and updated guidance to $145 million to $150 million of Q4 revenue, $553 million to $558 million for full-year revenue, and $163 million to $166 million of full-year adjusted EBITDA.
Analysts focused on Genesis monetization, pricing and whether spend is incremental or coming from existing budgets; management said early examples have been incremental funding, but it is still early and they do not yet know the long-term mix. Questions also probed sales-cycle friction and Corellium; management linked both to foreign-filer status and said redomiciliation has already helped customer conversations, while Corellium’s outlook remains at the lower end of the prior range. Other questions addressed hardware timing in Pathfinder and the broader move toward platform pricing, to which management said some hardware shipments slipped into Q4 and that future contracts will likely combine subscription, meter and usage-based elements with transparency for customers.
The call showed broad-based momentum: ARR, revenue and EBITDA all beat guidance, international growth remained strong, and U.S. Federal reaccelerated. Genesis is seeing real early adoption, with management describing customer urgency, expansion into multimodal evidence and on-prem demand, while the company also expects redomiciliation and product changes to reduce friction and improve predictability over time.
Management highlighted several headwinds: Corellium underperformed because of delayed renewals and churn tied to foreign-filer concerns, and the final tranche of Inseyets conversions should be less accretive than prior years. Revenue is also becoming more ratable as cloud and AI adoption rises, which lowers near-term hardware contribution and makes quarterly revenue mix less predictable, while larger cloud/AI deals and hardware sourcing can still affect timing.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 50.0%
- Shares Outstanding
- 251.34M
- Float Shares
- 125.78M
of shares held by institutions
215 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| True Wind Capital Management, L.P. | 13.86M | 0 |
| Voss Capital, LP | 12.49M | ▲ 1.04M |
| Pertento Partners Llp | 12.19M | ▲ 4.18M |
| Nomura Holdings Inc | 9.19M | ▲ 9.19M |
| Phoenix Financial Ltd. | 5.11M | ▼ 1.07M |
| Blackrock, Inc. | 4.40M | ▼ 1.28M |
| Philosophy Capital Management LLC | 4.07M | ▲ 4.07M |
| Think Investments LP | 3.30M | ▲ 3.30M |
| Citigroup Inc | 3.24M | ▲ 2.89M |
| Clal Insurance Enterprises Holdings Ltd | 2.77M | 0 |
| Morgan Stanley | 2.40M | ▲ 211.14K |
| Engine Capital Management, LP | 2.18M | ▲ 2.18M |
Held by 136 ETFs
Biggest fund positions in CLBT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Windham Holly B. | sell | 3,049 |
| Nov 16, 26 | Jewell Marcus | sell | 12,462 |
| Nov 17, 26 | Jewell Marcus | sell | 9,928 |
| Nov 12, 26 | GEE DAVID NICHOLAS | sell | 234 |
| Nov 12, 26 | Jewell Marcus | sell | 393 |
| Oct 16, 26 | Barter David | sell | 12,134 |
| Sep 17, 26 | Utsumi Ryusuke | other | 15,190 |
| Sep 17, 26 | Domnitz Yonatan | other | 15,190 |
| Sep 17, 26 | CLAMMER ADAM | other | 15,190 |
| Sep 24, 26 | Ramji Shiven | other | 38,505 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CLBT coverage
Recent articles, reports, and earnings notes.
Want a deeper read on CLBT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Cellebrite DI (CLBT) Securities Investigation Notice - Levi & Korsinsky
prnewswire.com · Nov 20
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Cellebrite DI (CLBT)
globenewswire.com · Nov 18
Cellebrite DI: Continuous Innovation Including AI Can Drive Growth
seekingalpha.com · Nov 15
Cellebrite DI Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Cellebrite DI (CLBT)
prnewswire.com · Nov 13
Cellebrite DI Ltd. (CLBT) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Cellebrite DI Q3 Earnings Call Highlights
marketbeat.com · Nov 12
Cellebrite DI Ltd. (CLBT) Q3 Earnings Meet Estimates
zacks.com · Nov 12
Cellebrite Reports Third-Quarter 2026 Results
prnewswire.com · Nov 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
